Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 5;18(13):7178.
doi: 10.3390/ijerph18137178.

Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe-Comparison of the Results of Multi-Center Registries

Maciej Kempa  1 , Andrzej Przybylski  2   3 , Szymon Budrejko  1 , Tomasz Fabiszak  4 , Michał Lewandowski  5 , Krzysztof Kaczmarek  6 , Mateusz Tajstra  7 , Marcin Grabowski  8 , Przemysław Mitkowski  9 , Stanisław Tubek  10 , Ewa Jędrzejczyk-Patej  11 , Radosław Lenarczyk  11 , Dariusz Jagielski  12 , Janusz Romanek  2   3 , Anna Rydlewska  13   14 , Zbigniew Orski  15 , Joanna Zakrzewska-Koperska  16 , Artur Filipecki  17 , Marcin Janowski  18 , Tatjana Potpara  19 , Serge Boveda  20
Affiliations

Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe-Comparison of the Results of Multi-Center Registries

Maciej Kempa et al. Int J Environ Res Public Health. .

Abstract

The implantation of a subcutaneous cardioverter-defibrillator (S-ICD) may be used instead of a traditional transvenous system to prevent sudden cardiac death. Our aim was to compare the characteristics of S-ICD patients from the multi-center registry of S-ICD implantations in Poland with the published results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI). We compared data of 137 Polish S-ICD patients with 68 patients from the ESSS-SICDI registry. The groups did not differ significantly in terms of sex, prevalence of ischemic cardiomyopathy, concomitant diseases, and the rate of primary prevention indication. Polish patients had more advanced heart failure (New York Heart Association (NYHA) class III: 11.7% vs. 2.9%, NYHA II: 48.9% vs. 29.4%, NYHA I: 39.4% vs. 67.7%, p < 0.05 each). Young age (75.9% vs. 50%, p < 0.05) and no vascular access (7.3% vs. 0%, p < 0.05) were more often indications for S-ICD. The percentage of patients after transvenous system removal due to infections was significantly higher in the Polish group (11% vs. 1.5%, p < 0.05). In the European population, S-ICD was more frequently chosen because of patients' active lifestyle and patients' preference (both 10.3% vs. 0%, p < 0.05). Our analysis shows that in Poland, compared to other European countries, subcutaneous cardioverters-defibrillators are being implanted in patients at a more advanced stage of chronic heart failure. The most frequent reason for choosing a subcutaneous system instead of a transvenous ICD is the young age of a patient.

Keywords: implantable cardioverter-defibrillator; subcutaneous implantable cardioverter-defibrillator; sudden cardiac death; ventricular arrhythmia.

PubMed Disclaimer

Conflict of interest statement

Maciej Kempa—received consultant fees or advisory board membership fees from: Abbott, Biotronik, Boston Scientific, Medtronic; Michal Lewandowski—lecture honoraria, travel expenses coverage from Boston Scientific and lecture honoraria from Abbott; Krzysztof Kaczmarek—proctoring fees from Boston Scientific; Marcin Grabowski—received consultant and lectures fees from Medtronic, Biotronik, Abbott and Boston Scientific; Przemysław Mitkowski—received consultant fees or research grants or advisory board membership fees from: Abbott, Biotronik, Boston Scientific, Medtronic; Stanislaw Tubek—received a consultancy fee from Boston Scientific; Ewa Jędrzejczyk–Patej—received consultant fees from Medtronic, Biotronik, Abbott and Boston Scientific; Radosław Lenarczyk—received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no 847999; Dariusz Jagielski—received a honorarium from Boston Scientific for a lecture during a webinar; Anna Rydlewska—consultant for Medtronic’s Warsaw Education Center; Serge Boveda—consultant for Medtronic, Boston Scietific, Microport and Zoll; Andrzej Przybylski, Szymon Budrejko, Tomasz Fabiszak, Mateusz Tajstra, Janusz Romanek, Zbigniew Orski, Joanna Zakrzewska-Koperska, Artur Filipecki, Marcin Janowski and Tatjana Potpara declared no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Rordorf R., Casula M., Pezza L., Fortuni F., Sanzo A., Savastano S., Vicentini A. Subcutaneous versus transvenous implantable defibrillator: An updated meta-analysis. Heart Rhythm. 2021;18:382–391. doi: 10.1016/j.hrthm.2020.11.013. - DOI - PubMed
    1. Knops R.E., Olde Nordkamp L.R., Delnoy P.P.H., Boersma L.V., Kuschyk J., El-Chami M.F., Bonnemeier H., Behr E.R., Brouwer T.F., Kääb S., et al. Subcutaneous or Transvenous Defibrillator Therapy. N. Engl. J. Med. 2020;383:526–536. doi: 10.1056/NEJMoa1915932. - DOI - PubMed
    1. Authors/Task Force Members. Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., Elliott P.M., Fitzsimons D., Hatala R., et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) Eur. Heart J. 2015;36:2793–2867. - PubMed
    1. Al-Khatib S.M., Stevenson W.G., Ackerman M.J., Bryant W.J., Callans D.J., Curtis A.B., Deal B.J., Dickfeld T., Field M.E., Fonarow G.C., et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15:e190–e252. - PubMed
    1. Kaczmarek K., Zwoliński R., Bartczak K., Ptaszyński P., Wranicz J.K. A subcutaneous implantable cardioverter-defibrillator—The first implantation in Poland. Kardiol. Pol. 2015;73:62. doi: 10.5603/KP.2015.0010. - DOI - PubMed